Heat Biologics, Inc. to Present at Aegis Capital Corp. 2013 Healthcare Conference

CHAPEL HILL, NC -- (Marketwired) -- 09/19/13 -- Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will present a company overview at the Aegis Capital Corp. 2013 Healthcare Conference in Las Vegas, NV on Thursday, September 26, 2013 at 9:00 a.m. Pacific Time.

About Heat Biologics:

Heat Biologics (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel off-the-shelf ImPACT therapeutic vaccines to combat a wide range of cancers. Our proprietary ImPACT Therapy is being designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat shock protein gp-96 is a chaperone protein found in all human cells. Heat's lead compound, HS-110, will be entering Phase 2 trials against non-small cell lung cancer and its second product candidate, HS-410 will be entering Phase 1/2 clinical trials against bladder cancer.

Heat Biologics, Inc. Contact Information:

Matthew Czajkowski
Chief Financial Officer
(919) 240 7133
Email Contact

Rhonda Chiger
Rx Communications Group
(917) 322-2569
Email Contact

Source: Heat Biologics, Inc.

Released September 19, 2013